Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 11:17 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1657–1680 of 33,598 matching trials from the live ClinicalTrials.gov search.
Conditions
Peripheral Arterial Disease, Paclitaxel Adverse Reaction, Safety Issues
Interventions
Retrospective data collection
Other
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
66 Years and older
Enrollment
168,553 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Neovascular Age-Related Macular Degeneration, Diabetic Macular Edema
Interventions
REGN910-3, REGN910, Intravitreal Aflibercept Injection (IAI)
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
5
States / cities
Beverly Hills, California • Winter Haven, Florida • Boston, Massachusetts + 2 more
Conditions
Heart Failure
Interventions
AMG 986
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
4
States / cities
Tustin, California • Orlando, Florida • Minneapolis, Minnesota + 1 more
Conditions
Eastern Equine Encephalitis
Interventions
Eastern Equine Encephalitis Vaccine, Inactivated, Dried, TSI-GSD 104
Biological
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
18 Years to 65 Years
Enrollment
138 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2018
U.S. locations
1
States / cities
Fort Deterick, Maryland
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

Study of Intravenous ZMA001 in Healthy Subjects

NCT05967299
Conditions
Pulmonary Arterial Hypertension PAH
Interventions
Placebo Cohort 1 (1.5 mg/kg/dose) only, ZMA001 (BC-NKA-20008)
Other · Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 60 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Cerebrovascular Accident
Interventions
Abciximab (ReoPro) and Reteplase (Retavase)
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years to 80 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2008
U.S. locations
3
States / cities
Washington D.C., District of Columbia • Bethesda, Maryland • Takoma Park, Maryland
Conditions
Chronic Immune Thrombocytopenia
Interventions
Panzyga
Biological
Lead sponsor
Octapharma
Industry
Eligibility
1 Year to 18 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
8
States / cities
Sacramento, California • Minneapolis, Minnesota • Rochester, Minnesota + 5 more
Conditions
Metastatic Solid Tumors, Refractory/Relapsed Hematologic Malignancies
Interventions
ARQ 621
Drug
Lead sponsor
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
4
States / cities
Phoenix, Arizona • Santa Monica, California • Boston, Massachusetts + 1 more
Conditions
Retinitis Pigmentosa
Interventions
Intravitreal autologous CD34+ cells
Biological
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Sacramento, California
Conditions
Neuropathic Pain From Lumbosacral Radiculopathy
Interventions
KLS-2031, Placebo
Drug · Other
Lead sponsor
Kolon Life Science
Industry
Eligibility
18 Years to 75 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Salt Lake City, Utah
Conditions
Metastatic Pancreatic Cancer
Interventions
RX-3117
Drug
Lead sponsor
Processa Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
10
States / cities
Tucson, Arizona • Weeki Wachee, Florida • Joliet, Illinois + 7 more
Completed Not applicable Interventional Accepts healthy volunteers Results available

FAST GFR: Pilot Study to Evaluate the Safety of the FAST GFR Test in Patients.

NCT01978314
Conditions
Chronic Kidney Disease, Acute Kidney Injury
Interventions
75 mg / 6 mL VFI™
Device
Lead sponsor
FAST BioMedical
Industry
Eligibility
19 Years to 75 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Birmingham, Alabama
Conditions
Glabellar Lines, Lateral Canthal Lines
Interventions
MT10109L, Placebo
Drug
Lead sponsor
Medy-Tox
Industry
Eligibility
18 Years and older
Enrollment
415 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
9
States / cities
Glendale, Arizona • Newport Beach, California • Coral Gables, Florida + 6 more
Conditions
Type 2 Diabetes
Interventions
Technosphere® Insulin Inhalation Powder, Insulin Aspart, Insulin Glargine
Drug
Lead sponsor
Mannkind Corporation
Industry
Eligibility
18 Years to 80 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
29
States / cities
Mobile, Alabama • Fresno, California • Long Beach, California + 22 more
Conditions
Myelodysplastic Syndromes
Interventions
Luspatercept, Epoetin Alfa
Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
402 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
33
States / cities
Clovis, California • Fountain Valley, California • Los Alamitos, California + 30 more
Conditions
Postoperative Ileus
Interventions
5% dextrose in water, TZP-101
Drug
Lead sponsor
Tranzyme, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
267 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
10
States / cities
Los Angeles, California • Miami, Florida • Ocala, Florida + 7 more
Conditions
Diagnosis of Adult Growth Hormone Deficiency (AGDH)
Interventions
AEZS-130 (formerly ARD-07), L-ARG+GHRH
Drug
Lead sponsor
AEterna Zentaris
Industry
Eligibility
18 Years and older
Enrollment
101 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2011
U.S. locations
13
States / cities
Tempe, Arizona • Los Angeles, California • Torrance, California + 9 more
Conditions
Cystic Fibrosis
Interventions
VX-121/TEZ/D-IVA, ELX/TEZ/IVA, IVA, Placebo (matched to VX-121/TEZ/D-IVA), Placebo (matched to ELX/TEZ/IVA), Placebo (matched to IVA)
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
12 Years and older
Enrollment
597 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
62
States / cities
Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 55 more
Conditions
Psoriasis
Interventions
AN2728 ointment, 2%, Ointment Vehicle
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
10
States / cities
New Haven, Connecticut • Louisville, Kentucky • Fridley, Minnesota + 7 more
Conditions
Migraine Prophylaxis
Interventions
Atogepant
Drug
Lead sponsor
AbbVie
Industry
Eligibility
6 Years to 17 Years
Enrollment
650 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2032
U.S. locations
35
States / cities
Huntsville, Alabama • Little Rock, Arkansas • Anaheim, California + 32 more
Conditions
Hematologic Neoplasms
Interventions
Hemanext ONE system, Conventional RBCs
Device
Lead sponsor
Hemanext
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Dry Eye
Interventions
EBI-005-1, EBI-005-1 Placebo
Drug
Lead sponsor
Eleven Biotherapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Tempe, Arizona
Conditions
Migraine
Interventions
Ubrogepant, Lu AG09222, Placebo
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
18 Years to 65 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
4
States / cities
Orlando, Florida • Atlanta, Georgia • Austin, Texas + 1 more
Conditions
Colitis, Crohn's Disease, Inflammatory Bowel Disease
Interventions
Immunologic Monitoring
Other
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years to 75 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland